Cyprotex offers new early drug discovery service
UK-based Cyprotex, a provider of techniques for evaluating drug delivery, has launched a new service to help drug companies to assess new oral drug candidates. The service, known as Cloe Screen PAMPA (Parallel Artificial Membrane Permeation Assay), provides a way of prioritising compounds based on their potential to cross the gut wall and is based on assessing very simple permeability properties.
UK-based Cyprotex, a provider of techniques for evaluating drug delivery, has launched a new service to help drug companies to assess new oral drug candidates. The service, known as Cloe Screen PAMPA (Parallel Artificial Membrane Permeation Assay), provides a way of prioritising compounds based on their potential to cross the gut wall and is based on assessing very simple permeability properties.
Cloe Screen PAMPA enables drug researchers to see how compounds behave in the different pH environments that exist throughout the entire gastro-intestinal tract. This gives an idea of how much of their compounds might reach their target organs in order to be effective therapies.
The assay was designed in collaboration with a partner company and is widely used by the pharmaceutical industry. It uses mass spectrometry (LC-MS/MS) as an end-point to ensure greater data accuracy and sensitivity than traditionally employed absorbance measurements.
Dr Darwin Cheney, Cyprotex's chief scientific officer, said: 'The Cloe Screen PAMPA offers our partners a high quality, fast turnaround assay that displays notable reproducibility. In addition, we have demonstrated that our assay shows several fold improvement in sensitivity over currently available PAMPA assays.'